Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dimethyl fumarate alters microglia phenotype and protects neurons against proinflammatory toxic microenvironments.

Journal of neuroimmunology - 15 Oct 2016

Peng Haiyan, Li Huo, Sheehy Adam, Cullen Patrick, Allaire Norm, Scannevin Robert H

Abstract excerpt

Delayed-release dimethyl fumarate (DMF) is an approved treatment for multiple sclerosis (MS). Microglia are considered central to MS pathophysiology, however the effects of DMF and the primary metabolite monomethyl fumarate (MMF) on microglia are not well characterized. We demonstrated that DMF and MMF altered transcriptional responses in primary microglia related to the nuclear factor (erythroid-derived 2)-like...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cellular Microenvironment
Share to Fumarates

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunosuppressive Agents

Share to Inflammation Mediators

Share to Microglia

Share to Neurons

Share to Neuroprotective Agents

Share to Rats, Sprague-Dawley

Source

Identifiers

PMID: 27725119
DOI: 10.1016/j.jneuroim.2016.08.006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dimethyl fumarate alters microglia phenotype and protects neurons against proinflammatory toxic microenvironments.PMID 27725119Read ↗

Pharmacodynamics of Dimethyl Fumarate Are Tissue Specific and Involve NRF2-Dependent and -Independent MechanismsSemantic proximity Read ↗

A novel fumarate, isosorbide di-(methyl fumarate) (IDMF), replicates astrocyte transcriptome responses to dimethyl fumarate (DMF) but specifically down-regulates genes linked to a reactive phenotype.Semantic proximity Read ↗

The Emerging Role of Dimethyl Fumarate in Alzheimer’s Disease—A Systematic Review of Available Preclinical StudiesSemantic proximity Read ↗

Repurposing the NRF2 Activator Dimethyl Fumarate as Therapy Against Synucleinopathy in Parkinson's Disease.Semantic proximity Read ↗

Transcriptomic profiling identifies ferroptosis and NF-κB signaling involved in α-dimorphecolic acid regulation of microglial inflammationSemantic proximity Read ↗

Real-world Safety and Efficacy of Dimethyl Fumarate in Relapse-Remitting Multiple Sclerosis Patients: A Regional Cohort Report of the Iranian PatientsSemantic proximity Read ↗

Fumaric acid esters stimulate astrocytic VEGF expression through HIF-1α and Nrf2.Semantic proximity Read ↗

Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.Semantic proximity Read ↗

Repurposing dimethyl fumarate as an antiepileptogenic and disease-modifying treatment for drug-resistant epilepsySemantic proximity Read ↗

Plasma microRNA Signature as Predictive Marker of Clinical Response to Therapy During Multiple SclerosisSemantic proximity Read ↗

Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case-control study protocol for dimethyl fumarate-induced lymphopenia.Semantic proximity Read ↗

Cell type-specific Nrf2 expression in multiple sclerosis lesionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.